Effect of chlorthalidone, amlodipine, and lisinopril on visit-to-visit variability of blood pressure: Results from the antihypertensive and lipid-lowering treatment to prevent heart attack trial

Journal of Clinical Hypertension

Volumn 16, Issue 5, 2014, Pages 323-330

  Muntner, Paul ^a,b   Levitan, Emily B ^a   Lynch, Amy I ^a   Simpson, Lara M ^c   Whittle, Jeffrey ^d,e   Davis, Barry R ^c   Kostis, John B ^f   Whelton, Paul K ^g   Oparil, Suzanne ^b  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b University of Alabama at Birmingham   (United States)

^c UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^d MEDICAL COLLEGE OF WISCONSIN   (United States)

^e CLEMENT J ZABLOCKI VETERANS AFFAIRS MEDICAL CENTER   (United States)

^f ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^g TULANE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; CHLORTALIDONE; DOXAZOSIN; LISINOPRIL; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ADULT; ANTIHYPERTENSIVE ACTIVITY; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE VARIABILITY; BLOOD PRESSURE VISIT TO VISIT VARIABILITY; CALCULATION; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; ACUTE CORONARY SYNDROME; AGED; AMBULATORY CARE; BLOOD PRESSURE; CLINICAL TRIAL; COMPLICATION; DOSE RESPONSE; DRUG COMBINATION; HYPERTENSION; MULTICENTER STUDY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROGNOSIS; RISK FACTOR; TREATMENT OUTCOME; UTILIZATION;

ACUTE CORONARY SYNDROME; AGED; AMLODIPINE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BLOOD PRESSURE DETERMINATION; CALCIUM CHANNEL BLOCKERS; CHLORTHALIDONE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERTENSION; HYPOLIPIDEMIC AGENTS; LISINOPRIL; MALE; OFFICE VISITS; PROGNOSIS; RISK FACTORS; TREATMENT OUTCOME;

EID: 84900401881     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/jch.12290     Document Type: Article

References (27)

1. Rothwell PM, Howard SC, Dolan E, et al. Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension. Lancet. 2010;375:895-905.
2. Muntner P, Shimbo D, Tonelli M, et al. The relationship between visit-to-visit variability in systolic blood pressure and all-cause mortality in the general population: findings from NHANES III, 1988 to 1994. Hypertension. 2011;57:160-166.
3. Shimbo D, Newman JD, Aragaki AK, et al. Association between annual visit-to-visit blood pressure variability and stroke in postmenopausal women: data from the Women's Health Initiative. Hypertension. 2012;60:625-630.
4. Muntner P, Krousel-Wood M, Hyre AD, et al. Antihypertensive prescriptions for newly treated patients before and after the main antihypertensive and lipid-lowering treatment to prevent heart attack trial results and seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure Guidelines. Hypertension. 2009;53:617-623.
5. Player MS, Gill JM, Fagan HB, Mainous AG 3rd. Antihypertensive prescribing practices: impact of the antihypertensive and lipid-lowering treatment to prevent heart attack trial. J Clin Hypertens. 2006;8:860-864.
6. Webb AJ, Fischer U, Mehta Z, Rothwell PM. Effects of antihypertensive-drug class on interindividual variation in blood pressure and risk of stroke: a systematic review and meta-analysis. Lancet. 2010;375:906-915.
7. Mancia G, Fagard R, Narkiewicz K, et al. 2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH/ESC Task Force for the Management of Arterial Hypertension. J Hypertens. 2013;31:1925-1938.
8. Davis BR, Cutler JA, Gordon DJ, et al. Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT Research Group. Am J Hypertens. 1996;9:342-360.
9. Dunnett CW. A multiple comparisons procedure for comparing several treatments with a control. J Am Stat Assoc. 1955;60:573-583.
10. ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA. 2000;283:1967-1975.
11. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981-2997.
12. Levitan EB, Kaciroti N, Oparil S, et al. Relationships between metrics of visit-to-visit variability of blood pressure. J Hum Hypertens. 2013;27:589-593.
13. Muntner P, Joyce C, Levitan EB, et al. Reproducibility of visit-to-visit variability of blood pressure measured as part of routine clinical care. J Hypertens. 2011;29:2332-2338.
14. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604-612.
15. Azur MJ, Stuart EA, Frangakis C, Leaf PJ. Multiple imputation by chained equations: what is it and how does it work? Int J Methods Psychiatr Res. 2011;20:40-49.
16. White IR, Royston P, Wood AM. Multiple imputation using chained equations: issues and guidance for practice. Stat Med. 2011;30:377-399.
17. Rothwell PM, Howard SC, Dolan E, et al. Effects of beta blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke. Lancet Neurol. 2010;9:469-480.
18. Mancia G, Facchetti R, Parati G, Zanchetti A. Visit-to-visit blood pressure variability in the European Lacidipine Study on Atherosclerosis: methodological aspects and effects of antihypertensive treatment. J Hypertens. 2012;30:1241-1251.
19. Rothwell PM. Limitations of the usual blood-pressure hypothesis and importance of variability, instability, and episodic hypertension. Lancet. 2010;375:938-948.
20. Mancia G. Short- and long-term blood pressure variability: present and future. Hypertension. 2012;60:512-517.
21. Diaz KM, Veerabhadrappa P, Kashem MA, et al. Relationship of visit-to-visit and ambulatory blood pressure variability to vascular function in African Americans. Hypertens Res. 2012;35:55-61.
22. Shan ZZ, Dai SM, Su DF. Arterial baroreflex deficit induced organ damage in sinoaortic denervated rats. J Cardiovasc Pharmacol. 2001;38:427-437.
23. Su DF. Treatment of hypertension based on measurement of blood pressure variability: lessons from animal studies. Curr Opin Cardiol. 2006;21:486-491.
24. Ichihara A, Kaneshiro Y, Sakoda M, et al. Add-on amlodipine improves arterial function and structure in hypertensive patients treated with an angiotensin receptor blocker. J Cardiovasc Pharmacol. 2007;49:161-166.
25. Zhu Z, Zhu S, Liu D, et al. Thiazide-like diuretics attenuate agonist-induced vasoconstriction by calcium desensitization linked to Rho kinase. Hypertension. 2005;45:233-239.
26. Pickering TG, Shimbo D, Haas D. Ambulatory blood-pressure monitoring. N Engl J Med. 2006;354:2368-2374.
27. Muntner P, Shimbo D, Diaz KM, et al. Low correlation between visit-to-visit variability and 24-h variability of blood pressure. Hypertens Res. 2013;36:940-946.